ergovaline has been researched along with sulpiride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camden, JM; Kerley, MS; Larson, BT; Paterson, JA; Piper, EL; Samford, MD; Turner, JT | 1 |
| Birrenkott, GP; Cross, DL; Grimes, LW; Strickland, JR | 1 |
2 other study(ies) available for ergovaline and sulpiride
| Article | Year |
|---|---|
Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells.
Topics: Adenosine Monophosphate; Animals; Cell Membrane; Ergotamines; Pituitary Neoplasms; Radioligand Assay; Rats; Receptors, Dopamine D2; Second Messenger Systems; Sulpiride; Transfection; Tumor Cells, Cultured; Vasoactive Intestinal Peptide; Vasoconstrictor Agents | 1995 |
Effect of ergovaline, loline, and dopamine antagonists on rat pituitary cell prolactin release in vitro.
Topics: Alkaloids; Animals; Cells, Cultured; Domperidone; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Ergotamines; Male; Pituitary Gland; Prolactin; Radioimmunoassay; Rats; Rats, Wistar; Sulpiride; Vasoconstrictor Agents | 1994 |